JZ-IV-10 – (807342-16-1)

JZ-IV-10 is a biochemical compound classified as a triple reuptake inhibitor (TRI), designed to inhibit the reuptake of serotonin, norepinephrine, and dopamine. It was developed by Accenta Pharmaceuticals. JZ-IV-10 exhibits a ‘balanced’ affinity for all three monoamine transporters, making it a promising candidate for the treatment of depression and potentially other central nervous system disorders.

The development of JZ-IV-10 was inspired by the eugeroic modafinil, which was used as a lead compound to enhance its potency and selectivity. This hybrid approach combined the key pharmacophoric moieties of Nocaine, a selective DAT/NET inhibitor, and Modafinil, a DAT-preferring compound, to create a molecule with improved potency and affinity for all three transporters.

In preclinical studies, JZ-IV-10 has demonstrated significant in vivo efficacy in reducing immobility in animal models of depression, such as the forced swim test (FST) and the tail suspension test (TST). These studies suggest that JZ-IV-10 could offer a faster onset of action and greater efficacy compared to traditional antidepressants like selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs).

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

JZ-IV-10 is a biochemical compound classified as a triple reuptake inhibitor (TRI), designed to inhibit the reuptake of serotonin, norepinephrine, and dopamine. It was developed by Accenta Pharmaceuticals. JZ-IV-10 exhibits a ‘balanced’ affinity for all three monoamine transporters, making it a promising candidate for the treatment of depression and potentially other central nervous system disorders.

The development of JZ-IV-10 was inspired by the eugeroic modafinil, which was used as a lead compound to enhance its potency and selectivity. This hybrid approach combined the key pharmacophoric moieties of Nocaine, a selective DAT/NET inhibitor, and Modafinil, a DAT-preferring compound, to create a molecule with improved potency and affinity for all three transporters.

In preclinical studies, JZ-IV-10 has demonstrated significant in vivo efficacy in reducing immobility in animal models of depression, such as the forced swim test (FST) and the tail suspension test (TST). These studies suggest that JZ-IV-10 could offer a faster onset of action and greater efficacy compared to traditional antidepressants like selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs).

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/JZ-IV-10
https://pubchem.ncbi.nlm.nih.gov/compound/11291199
https://www.medkoo.com/products/58905
https://pmc.ncbi.nlm.nih.gov/articles/PMC4976848/
https://www.researchgate.net/publication/51368584_Piperidine-Based_NocaineModafinil_Hybrid_Ligands_as_Highly_Potent_Monoamine_Transporter_Inhibitors_Efficient_Drug_Discovery_by_Rational_Lead_Hybridization

IUPAC Name	2-[[(3R, 4S)-4-(4-chlorophenyl)-1-methylpiperidin-3-yl]methylsulfanyl]-N-propan-2-ylacetamide
CAS	807342-16-1
Molecular Weight	354.9
Molecular Formula	C18H27ClN2OS
SMILES	CC(C)NC(=O)CSC[C@H]1CN(CC[C@@H]1C2=CC=C(C=C2)Cl)C